ATE335497T1 - Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut - Google Patents

Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut

Info

Publication number
ATE335497T1
ATE335497T1 AT00929174T AT00929174T ATE335497T1 AT E335497 T1 ATE335497 T1 AT E335497T1 AT 00929174 T AT00929174 T AT 00929174T AT 00929174 T AT00929174 T AT 00929174T AT E335497 T1 ATE335497 T1 AT E335497T1
Authority
AT
Austria
Prior art keywords
subject
improved method
treating
blood
treating mammals
Prior art date
Application number
AT00929174T
Other languages
English (en)
Inventor
Anthony E Bolton
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of ATE335497T1 publication Critical patent/ATE335497T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/13—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/369—Temperature treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
    • A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00929174T 1999-05-06 2000-05-08 Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut ATE335497T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002271190A CA2271190A1 (en) 1999-05-06 1999-05-06 Improved method for treating mammals with modified mammalian blood

Publications (1)

Publication Number Publication Date
ATE335497T1 true ATE335497T1 (de) 2006-09-15

Family

ID=4163523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929174T ATE335497T1 (de) 1999-05-06 2000-05-08 Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut

Country Status (7)

Country Link
US (2) US6986888B1 (de)
EP (1) EP1181026B1 (de)
AT (1) ATE335497T1 (de)
AU (1) AU4738500A (de)
CA (1) CA2271190A1 (de)
DE (1) DE60029948D1 (de)
WO (1) WO2000067764A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045124B1 (en) 1999-01-12 2006-05-16 Vasogen Irelend Limited Pre-conditioning against cell death
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2327630A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Transforming growth factor regulation
US20100318014A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of acute ischemic brain stroke with ozone
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US20100316727A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of inflammatory disorders with ozone
WO2005097145A1 (en) * 2004-04-12 2005-10-20 Vasogen Ireland Limited Myocarditis treatment
EP1773360A4 (de) * 2004-07-20 2009-09-02 Vasogen Ireland Ltd Behandlung von akuten entzündlichen zuständen
AU2010260467A1 (en) * 2009-06-19 2012-02-09 Acquisci, Inc. Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
WO2013071281A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8704467U1 (de) 1987-01-15 1988-05-26 Quarzlampenfabrik Dr.-Ing. Felix W. Müller GmbH & Co KG, 45239 Essen Gerät zur Herstellung von oxygeniertem Blut
NZ249176A (en) 1992-02-07 1996-11-26 Vasogen Inc Method of increasing concentration of nitric oxide in blood using ozone and uv radiation
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US5591457A (en) 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
NZ306395A (en) 1995-05-05 2000-02-28 Vasogen Inc Treatment of blood to remove symptoms of vascular disorders by elevation of temperature, ultraviolet radiation or treatment with an oxidative environment
PT1011696E (pt) 1997-09-12 2004-03-31 Vasogen Ireland Ltd Tratamento do stresse e precondicoes contra o stresse
US6136308A (en) * 1997-09-12 2000-10-24 Vasogen Ireland Limited Treatment of stress and preconditioning against stress
AU768300B2 (en) 1998-11-13 2003-12-04 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals
CA2269364A1 (en) 1999-04-19 2000-10-19 Vasogen Ireland Limited Treatment of inflammatory and allergic disorders
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure

Also Published As

Publication number Publication date
US6986888B1 (en) 2006-01-17
EP1181026A2 (de) 2002-02-27
US7223391B2 (en) 2007-05-29
US20050238623A1 (en) 2005-10-27
DE60029948D1 (de) 2006-09-21
EP1181026B1 (de) 2006-08-09
CA2271190A1 (en) 2000-11-06
AU4738500A (en) 2000-11-21
WO2000067764A3 (en) 2001-02-08
WO2000067764A2 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
ATE281840T1 (de) Behandlung von diarrhoe
ATE155043T1 (de) Behandlung von autoimmun- und entzundungskrankheiten
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin
DE69616375D1 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
DE60029948D1 (de) Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
ATE61523T1 (de) Mittel zur verabreichung von hyaluronsaeure an saeuger.
ATE220400T1 (de) Trizyklische verbindungen zur behandlung von zellproliferativen störungen
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
FI932390A0 (fi) Nya hydroxiaminsyra- och N-hydroxiureaderivat samt deras anvaendning
NO951000L (no) Fremgangsmåte for reduksjon av blodnivåer av totalt kolesterol og lavdensitets lipoprotein-kolesterol
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE3750235D1 (de) Behandlung von autoimmunen Krankheiten mit Immunoverstärkungssubstanzen.
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
NO955258L (no) Medisinsk anvendelse av enzymer
DE59206872D1 (de) Verwendung von torasemid zur behandlung von hirnödemen
NO170661C (no) Anordning for behandling av yngel paa tidlige utviklingsstadier
NO925048D0 (no) Arylalkylestere av 4,5-dihydroksy-9,10-dihydro-9,10-diokso-2-antracenkarboksylsyre med terapeutisk aktivitet
ATE245991T1 (de) Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin
DK532087D0 (da) Farmaceutiske praeparater til behandling af hjernelidelser paa funktional og organisk basis
ATE31022T1 (de) Verwendung von 4,5'-azo-bis-salicylsaeure zur herstellung eines arzneimittels zur behandlung entzuendlicher darmkrankheiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties